Acute treatments: some blind alleys

Area of Science:

• Neuroscience
• Pharmacology
• Drug Development

Background:

• Sumatriptan, a selective 5-HT(1B/1D) agonist, initiated a new phase in migraine treatment research.
• Numerous novel therapeutic targets for migraine have been identified and clinically evaluated.
• The goal is to develop migraine treatments with superior efficacy and safety.

Purpose of the Study:

• To review and discuss unsuccessful strategies in anti-migraine drug development.
• To identify specific drug candidates and targets that did not lead to approved therapies.
• To analyze the reasons for failure, including lack of clinical efficacy and preclinical toxicity.

Main Methods:

• Review of clinical trial data and preclinical studies for anti-migraine drug candidates.
• Analysis of specific drug classes and individual compounds that failed in development.
• Categorization of failures based on efficacy or toxicity.

Main Results:

• Several promising targets, including NK-1 antagonists, second-generation 5-HT(1B/1D) agonists, and endothelin-1 antagonists, did not succeed.
• Specific compounds like CP-122,288, 4991W93, ganaxolone, LY334370 (5-HT1F agonist), and PNU-142,633 (5-HT1D agonist) were unsuccessful.
• Failures were attributed to insufficient clinical efficacy or unacceptable preclinical toxicity.

Conclusions:

• The development of effective and safe migraine treatments remains challenging.
• Understanding past failures is crucial for guiding future anti-migraine drug discovery efforts.
• Identifying and avoiding "blind alleys" can optimize resource allocation in pharmaceutical research.